ISLR and non-small cell lung carcinoma: In the present study, we showed that the proportion of Meflin+ CAFs in tumor stroma correlated with a favorable response to ICB therapy in patients with non-small cell lung cancer (NSCLC) and mouse syngeneic tumor models.